A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study)

for National Research Group on Idiopathic Bone Marrow Failure Syndromes

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hypoplastic myelodysplastic syndrome (hMDS) is a distinct entity with bone marrow (BM) hypocellularity and the risk of death from BM failure (BMF). To elucidate the characteristics of hMDS, the data of 129 patients diagnosed between April 2003 and March 2012 were collected from 20 institutions and the central review team of the National Research Group on Idiopathic Bone Marrow Failure Syndromes, and compared with 115 non-hMDS patients. More RA and fewer CMMoL and RAEB-t in French-American-British (FAB) and more RCUD and MDS-U and fewer RCMD in World Health Organization (WHO) classifications were found in hMDS than non-hMDS with significant differences. The overall survival (OS) and AML progression-free survival (AML-PFS) of hMDS were higher than those of non-hMDS, especially in patients at age ≥50 and of lower risk in Revised International Prognostic Scoring System (IPSS-R). In competing risks analysis, hMDS exhibited decreased risk of AML-progression in lower IPSS or IPSS-R risk patients, and higher risk of death from BMF in patients at age ≥50. Poor performance status (PS ≥2) and high karyotype risks in IPSS-R (high and very high) were significant risk factors of death and AML-progression in Cox proportional hazards analysis.

Original languageEnglish
Pages (from-to)1324-1332
Number of pages9
JournalAmerican Journal of Hematology
Volume92
Issue number12
DOIs
Publication statusPublished - 01-12-2017

Fingerprint

Myelodysplastic Syndromes
Multicenter Studies
Retrospective Studies
Bone Marrow
Refractory Anemia with Excess of Blasts
Surveys and Questionnaires
Karyotype
Disease-Free Survival
Survival
Research

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

for National Research Group on Idiopathic Bone Marrow Failure Syndromes. / A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). In: American Journal of Hematology. 2017 ; Vol. 92, No. 12. pp. 1324-1332.
@article{4b419834468a4376afde23cde2ccd23e,
title = "A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study)",
abstract = "Hypoplastic myelodysplastic syndrome (hMDS) is a distinct entity with bone marrow (BM) hypocellularity and the risk of death from BM failure (BMF). To elucidate the characteristics of hMDS, the data of 129 patients diagnosed between April 2003 and March 2012 were collected from 20 institutions and the central review team of the National Research Group on Idiopathic Bone Marrow Failure Syndromes, and compared with 115 non-hMDS patients. More RA and fewer CMMoL and RAEB-t in French-American-British (FAB) and more RCUD and MDS-U and fewer RCMD in World Health Organization (WHO) classifications were found in hMDS than non-hMDS with significant differences. The overall survival (OS) and AML progression-free survival (AML-PFS) of hMDS were higher than those of non-hMDS, especially in patients at age ≥50 and of lower risk in Revised International Prognostic Scoring System (IPSS-R). In competing risks analysis, hMDS exhibited decreased risk of AML-progression in lower IPSS or IPSS-R risk patients, and higher risk of death from BMF in patients at age ≥50. Poor performance status (PS ≥2) and high karyotype risks in IPSS-R (high and very high) were significant risk factors of death and AML-progression in Cox proportional hazards analysis.",
author = "{for National Research Group on Idiopathic Bone Marrow Failure Syndromes} and Takashi Kobayashi and Yasuhito Nannya and Motoshi Ichikawa and Kenji Oritani and Yuzuru Kanakura and Akihiro Tomita and Hitoshi Kiyoi and Masayoshi Kobune and Junji Kato and Hiroshi Kawabata and Motohiro Shindo and Yoshihiro Torimoto and Yuji Yonemura and Nobuyoshi Hanaoka and Hideki Nakakuma and Daisuke Hasegawa and Atsushi Manabe and Naohito Fujishima and Nobuharu Fujii and Mitsune Tanimoto and Yasuyoshi Morita and Akira Matsuda and Atsushi Fujieda and Naoyuki Katayama and Haruhiko Ohashi and Hirokazu Nagai and Yoshiki Terada and Masayuki Hino and Ken Sato and Naoshi Obara and Shigeru Chiba and Kensuke Usuki and Masatsugu Ohta and Osamu Imataki and Makiko Uemura and Tomoiku Takaku and Norio Komatsu and Akira Kitanaka and Kazuya Shimoda and Kenichiro Watanabe and Kaoru Tohyama and Akifumi Takaori-Kondo and Hideo Harigae and Shunya Arai and Yasushi Miyazaki and Keiya Ozawa and Mineo Kurokawa",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/ajh.24905",
language = "English",
volume = "92",
pages = "1324--1332",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",

}

for National Research Group on Idiopathic Bone Marrow Failure Syndromes 2017, 'A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study)', American Journal of Hematology, vol. 92, no. 12, pp. 1324-1332. https://doi.org/10.1002/ajh.24905

A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). / for National Research Group on Idiopathic Bone Marrow Failure Syndromes.

In: American Journal of Hematology, Vol. 92, No. 12, 01.12.2017, p. 1324-1332.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study)

AU - for National Research Group on Idiopathic Bone Marrow Failure Syndromes

AU - Kobayashi, Takashi

AU - Nannya, Yasuhito

AU - Ichikawa, Motoshi

AU - Oritani, Kenji

AU - Kanakura, Yuzuru

AU - Tomita, Akihiro

AU - Kiyoi, Hitoshi

AU - Kobune, Masayoshi

AU - Kato, Junji

AU - Kawabata, Hiroshi

AU - Shindo, Motohiro

AU - Torimoto, Yoshihiro

AU - Yonemura, Yuji

AU - Hanaoka, Nobuyoshi

AU - Nakakuma, Hideki

AU - Hasegawa, Daisuke

AU - Manabe, Atsushi

AU - Fujishima, Naohito

AU - Fujii, Nobuharu

AU - Tanimoto, Mitsune

AU - Morita, Yasuyoshi

AU - Matsuda, Akira

AU - Fujieda, Atsushi

AU - Katayama, Naoyuki

AU - Ohashi, Haruhiko

AU - Nagai, Hirokazu

AU - Terada, Yoshiki

AU - Hino, Masayuki

AU - Sato, Ken

AU - Obara, Naoshi

AU - Chiba, Shigeru

AU - Usuki, Kensuke

AU - Ohta, Masatsugu

AU - Imataki, Osamu

AU - Uemura, Makiko

AU - Takaku, Tomoiku

AU - Komatsu, Norio

AU - Kitanaka, Akira

AU - Shimoda, Kazuya

AU - Watanabe, Kenichiro

AU - Tohyama, Kaoru

AU - Takaori-Kondo, Akifumi

AU - Harigae, Hideo

AU - Arai, Shunya

AU - Miyazaki, Yasushi

AU - Ozawa, Keiya

AU - Kurokawa, Mineo

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Hypoplastic myelodysplastic syndrome (hMDS) is a distinct entity with bone marrow (BM) hypocellularity and the risk of death from BM failure (BMF). To elucidate the characteristics of hMDS, the data of 129 patients diagnosed between April 2003 and March 2012 were collected from 20 institutions and the central review team of the National Research Group on Idiopathic Bone Marrow Failure Syndromes, and compared with 115 non-hMDS patients. More RA and fewer CMMoL and RAEB-t in French-American-British (FAB) and more RCUD and MDS-U and fewer RCMD in World Health Organization (WHO) classifications were found in hMDS than non-hMDS with significant differences. The overall survival (OS) and AML progression-free survival (AML-PFS) of hMDS were higher than those of non-hMDS, especially in patients at age ≥50 and of lower risk in Revised International Prognostic Scoring System (IPSS-R). In competing risks analysis, hMDS exhibited decreased risk of AML-progression in lower IPSS or IPSS-R risk patients, and higher risk of death from BMF in patients at age ≥50. Poor performance status (PS ≥2) and high karyotype risks in IPSS-R (high and very high) were significant risk factors of death and AML-progression in Cox proportional hazards analysis.

AB - Hypoplastic myelodysplastic syndrome (hMDS) is a distinct entity with bone marrow (BM) hypocellularity and the risk of death from BM failure (BMF). To elucidate the characteristics of hMDS, the data of 129 patients diagnosed between April 2003 and March 2012 were collected from 20 institutions and the central review team of the National Research Group on Idiopathic Bone Marrow Failure Syndromes, and compared with 115 non-hMDS patients. More RA and fewer CMMoL and RAEB-t in French-American-British (FAB) and more RCUD and MDS-U and fewer RCMD in World Health Organization (WHO) classifications were found in hMDS than non-hMDS with significant differences. The overall survival (OS) and AML progression-free survival (AML-PFS) of hMDS were higher than those of non-hMDS, especially in patients at age ≥50 and of lower risk in Revised International Prognostic Scoring System (IPSS-R). In competing risks analysis, hMDS exhibited decreased risk of AML-progression in lower IPSS or IPSS-R risk patients, and higher risk of death from BMF in patients at age ≥50. Poor performance status (PS ≥2) and high karyotype risks in IPSS-R (high and very high) were significant risk factors of death and AML-progression in Cox proportional hazards analysis.

UR - http://www.scopus.com/inward/record.url?scp=85030463559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030463559&partnerID=8YFLogxK

U2 - 10.1002/ajh.24905

DO - 10.1002/ajh.24905

M3 - Article

C2 - 28891083

AN - SCOPUS:85030463559

VL - 92

SP - 1324

EP - 1332

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 12

ER -

for National Research Group on Idiopathic Bone Marrow Failure Syndromes. A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). American Journal of Hematology. 2017 Dec 1;92(12):1324-1332. https://doi.org/10.1002/ajh.24905